Neuste Beiträge aus: Cel-Sci Corp. (CVM; 871006)
Diskussionsstatistik
Anzahl Beiträge: 7.263
Aufrufe gesamt: 403.242
Aufrufe heute: 13
Diskussionsnr.: 791.230
Aufrufe gesamt: 403.242
Aufrufe heute: 13
Diskussionsnr.: 791.230
WKN: 871006
ISIN: US1508374097
Symbol: LSR
ISIN: US1508374097
Symbol: LSR
| 0,334 |
|
+8,44 % +0,026 |
Berlin (EUR), 25.05.12 | 08:08
Beitrag schreiben
Beliebteste Beiträge
Ansicht
- Chronologische Sortierung
- 500 Beiträge pro Seite
ALF-FRED
schrieb am 25.05.12 06:56:44
Beitrag Nr.7263
(43.209.361)
Bewertung: 1 x
Antwort
Zitat
Plaste
schrieb am 22.05.12 14:23:54
Beitrag Nr.7262
(43.196.499)
Bewertung: 1 x
Antwort
Zitat
schau mal da:
http://www.biomedreports.com/2012052295011/darling-dendreon-…
also Dendreon wurde auf Grund der Kosten für Provenge abgestraft. Wußten wir das nicht schon länger ?!
http://www.biomedreports.com/2012052295011/darling-dendreon-…
also Dendreon wurde auf Grund der Kosten für Provenge abgestraft. Wußten wir das nicht schon länger ?!
binda
schrieb am 21.05.12 21:13:08
Beitrag Nr.7261
(43.193.655)
Antwort
Zitat
Expertchen007
schrieb am 21.05.12 15:34:35
Beitrag Nr.7260
(43.192.008)
Antwort
Zitat
1 Tag hab ich Plus 10 %...dann 1 Tag Minus 10 %...so ist das
langweilig
ALF-FRED
schrieb am 21.05.12 06:20:33
Beitrag Nr.7259
(43.189.899)
Antwort
Zitat
Antwort auf Beitrag Nr.:
43.189.653 von binda am 20.05.12
23:14:06Geduld hab ich, nächstes Jahr ist 10 jähriges
bei mir mit der Aktie 
binda
schrieb am 20.05.12 23:14:06
Beitrag Nr.7258
(43.189.653)
Antwort
Zitat
Antwort auf Beitrag Nr.:
43.187.795 von Plaste am 20.05.12
01:33:10Ich habe mir die Beiträge durchgelesen, und kann
wieder nur sagen:die ersten Phase III- Ergebnisse dauern noch
mindestens bis Ende des Jahres, und wer diese Geduld nicht hat ,
ist zu früh eingestiegen.
Gruß binda
Gruß binda
Plaste
schrieb am 20.05.12 01:33:10
Beitrag Nr.7257
(43.187.795)
Antwort
Zitat
Plaste
schrieb am 19.05.12 09:46:11
Beitrag Nr.7256
(43.185.883)
Antwort
Zitat
Antwort auf Beitrag Nr.:
43.185.722 von MogD am 19.05.12
07:31:52Hallo,
Das war ja wie immer.
Es sind vermutlich viele Zocker rein, die dachten auf dem Meeting gibts News die den Kurs abgehen lassen. Insgeheim hatte ich das auch ein bischen gehofft.
Wobei wir ja wissen, das bei den Meetings von CVM meistens keine wirlich wichtigen News raus kommen.
"Bis 2015 ist noch lange hin...."
So lange werden wir nicht warten müssen.
Ich hoffe das wir, 4-8 Wochen nach Beendigung der Impfungen die ersten Ergebnisse bekommen.
Wann nun die Impfungen angefangen/ beendet werden würde mich eigentlich nur brennend interessieren?
Allen ein schönes WE
Plaste
Das war ja wie immer.
Es sind vermutlich viele Zocker rein, die dachten auf dem Meeting gibts News die den Kurs abgehen lassen. Insgeheim hatte ich das auch ein bischen gehofft.
Wobei wir ja wissen, das bei den Meetings von CVM meistens keine wirlich wichtigen News raus kommen.
"Bis 2015 ist noch lange hin...."
So lange werden wir nicht warten müssen.
Ich hoffe das wir, 4-8 Wochen nach Beendigung der Impfungen die ersten Ergebnisse bekommen.
Wann nun die Impfungen angefangen/ beendet werden würde mich eigentlich nur brennend interessieren?
Allen ein schönes WE
Plaste
MogD
schrieb am 19.05.12 07:31:52
Beitrag Nr.7255
(43.185.722)
Antwort
Zitat
Antwort auf Beitrag Nr.:
43.184.562 von Plaste am 18.05.12
19:54:11Wenn ich mir den Kursverfall pünktlich zum Start
des Shareholder Meetings so anschaue, war das wohl kein großer
Erfolg. 
News selbst habe ich bei Cel bisher noch nicht gefunden.
Eigentlich also alles wie immer - großer Hype, kurzer Anstieg, rasanter Absturz. Bis 2015 ist noch lange hin....
News selbst habe ich bei Cel bisher noch nicht gefunden.
Eigentlich also alles wie immer - großer Hype, kurzer Anstieg, rasanter Absturz. Bis 2015 ist noch lange hin....
Plaste
schrieb am 18.05.12 19:54:11
Beitrag Nr.7254
(43.184.562)
Antwort
Zitat
Aber war heute nicht das Shareholder Meeting?
warten wir mal ab....
mfg Plaste
schlumpftrader
schrieb am 18.05.12 16:51:24
Beitrag Nr.7253
(43.183.339)
Antwort
Zitat
hallo,
wie gewonnen, so zerronnen
leider :-(
na ja, noch ist ja nicht aller tage abend.
bye
schlumpftrader
wie gewonnen, so zerronnen
leider :-(
na ja, noch ist ja nicht aller tage abend.
bye
schlumpftrader
ALF-FRED
schrieb am 18.05.12 16:21:17
Beitrag Nr.7252
(43.183.145)
Antwort
Zitat
VIENNA, Va.--(BUSINESS WIRE)--
The following letter was provided to shareholders by CEL-SCI Corporation (NYSE MKT: CVM) for today’s annual shareholder meeting:
Dear Fellow Shareholders:
Last year, 2011, was an exciting year for us because we were finally able to start our Phase III clinical trial for our investigational cancer drug Multikine® (Leukocyte Interleukin, Injection)*. This trial is the largest head and neck cancer study ever conducted in the world and is designed to hopefully give us approval to market Multikine throughout the world.
This trial, which is designed to prove to the most rigorous standards that Multikine works, was launched in dozens of hospitals located in eight countries on three continents. All of us at CEL-SCI are very proud of this major accomplishment. If we are successful in proving that the addition of Multikine to the current cancer therapies increases the patients’ overall survival, we would then expect to submit the Multikine drug dossier to regulatory agencies around the world for approval.
It has been a long road to this point, but that appears to be the norm for a “first in a new class” drug such as Multikine. Our vision for Multikine has always been that, by activating the immune response against the cancer, it could be a useful addition to the current treatment options used by cancer patients and doctors – and that it should add little to no toxicity to the existing treatments being used. With this vision in mind we selected head and neck cancer, a hard to treat and devastating disease, as a first target for Multikine. Head and neck cancer represents a clear unmet medical need, and there is currently one standard of care for its treatment worldwide. By adding Multikine to the current standard of care we hope to improve the overall survival currently achievable in these patients. As only little progress has been achieved in these patients in the past 50 years, this would be seen as a major achievement.
We carefully planned for, designed, and now are executing our Phase III clinical trial to the highest standard because we recognize that this is what it takes to succeed. We built a fully validated manufacturing facility near Baltimore, Maryland, USA, to ensure that the Multikine used in our Phase III trial would be consistent from lot to lot. Our study was intentionally designed to be very large and international in scope to improve our chances that the study results would be sufficiently robust so that it would not be required by the regulatory authorities that we conduct multiple studies to achieve approval of Multikine for commercial distribution. The international scope of the study will also increase rate of enrollment in the study so the study may be completed more rapidly, and allow us to submit applications for approval in multiple countries around the world. It is our strong belief that this study will prove that Multikine treatment will increase the overall survival of head and neck cancer patients.
The following is a brief summary of the key operational successes in 2011:
• Our Phase III study for Multikine started in one US cancer center in the final days of 2010. During 2011 we initiated 36 additional hospitals in 8 countries on three continents. That is a very fast pace for adding clinical sites to an international study.
• Patients were enrolled in the study on all three continents (North America, Europe and Asia).
• Our partners Teva Pharmaceuticals Industries (Israel) and Orient Europharma (Taiwan) enrolled patients in their respective territories.
• We produced multiple lots of Multikine in our manufacturing facility near Baltimore, Maryland, USA and provided drug in sufficient amounts at all clinical sites.
I am constantly being asked how the study is going. As you may know, I am not allowed to discuss the study results at this early stage. However, that being said, our confidence may be best expressed by the decision made to expand the trial into four extra territories at additional expense and effort, with the help of our partner Teva in certain areas. We are doing so because we want to complete the study to prove Multikine’s effectiveness as quickly as possible and hopefully receive marketing approval from the regulators.
If we are able to replicate the promising results seen in our earlier studies and prove that Multikine increases the overall survival of cancer patients by 10% (the study’s primary end point) or more, how much value will this create for our shareholders? No one knows exactly, but it should be significant. By way of example, in 2011 we witnessed the largest acquisition ever of a company with products still in clinical development, not yet on the market. Gilead Sciences bought Pharmasset (Hepatitis C) for about $11 billion in cash. The take home message from this acquisition is clear. Established pharmaceutical companies are willing to pay very large amounts of money for products that address both a large market and represent an unmet medical need. They prefer to wait until most of the risk has been taken off the table. Multikine addresses advanced primary (not yet treated) head and neck cancer, about 5-6% of the world’s cancer cases, clearly a large market. Advanced primary head and neck cancer also represents a clear unmet medical need.
The processes of manufacturing of biological substances and running clinical trials in cancer are extremely complex. We are able to do both because we have assembled a team of world experts who share our vision to help cancer patients. We thank you for your continued support and wish you a very happy, healthy and prosperous 2012.
Sincerely,
Geert Kersten
Maximilian de Clara
Chief Executive Officer
President
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
When used in this report, the words "intends," "believes," "anticipated," “plans” and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2011. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
.
.
Contact:.
.
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
The following letter was provided to shareholders by CEL-SCI Corporation (NYSE MKT: CVM) for today’s annual shareholder meeting:
Dear Fellow Shareholders:
Last year, 2011, was an exciting year for us because we were finally able to start our Phase III clinical trial for our investigational cancer drug Multikine® (Leukocyte Interleukin, Injection)*. This trial is the largest head and neck cancer study ever conducted in the world and is designed to hopefully give us approval to market Multikine throughout the world.
This trial, which is designed to prove to the most rigorous standards that Multikine works, was launched in dozens of hospitals located in eight countries on three continents. All of us at CEL-SCI are very proud of this major accomplishment. If we are successful in proving that the addition of Multikine to the current cancer therapies increases the patients’ overall survival, we would then expect to submit the Multikine drug dossier to regulatory agencies around the world for approval.
It has been a long road to this point, but that appears to be the norm for a “first in a new class” drug such as Multikine. Our vision for Multikine has always been that, by activating the immune response against the cancer, it could be a useful addition to the current treatment options used by cancer patients and doctors – and that it should add little to no toxicity to the existing treatments being used. With this vision in mind we selected head and neck cancer, a hard to treat and devastating disease, as a first target for Multikine. Head and neck cancer represents a clear unmet medical need, and there is currently one standard of care for its treatment worldwide. By adding Multikine to the current standard of care we hope to improve the overall survival currently achievable in these patients. As only little progress has been achieved in these patients in the past 50 years, this would be seen as a major achievement.
We carefully planned for, designed, and now are executing our Phase III clinical trial to the highest standard because we recognize that this is what it takes to succeed. We built a fully validated manufacturing facility near Baltimore, Maryland, USA, to ensure that the Multikine used in our Phase III trial would be consistent from lot to lot. Our study was intentionally designed to be very large and international in scope to improve our chances that the study results would be sufficiently robust so that it would not be required by the regulatory authorities that we conduct multiple studies to achieve approval of Multikine for commercial distribution. The international scope of the study will also increase rate of enrollment in the study so the study may be completed more rapidly, and allow us to submit applications for approval in multiple countries around the world. It is our strong belief that this study will prove that Multikine treatment will increase the overall survival of head and neck cancer patients.
The following is a brief summary of the key operational successes in 2011:
• Our Phase III study for Multikine started in one US cancer center in the final days of 2010. During 2011 we initiated 36 additional hospitals in 8 countries on three continents. That is a very fast pace for adding clinical sites to an international study.
• Patients were enrolled in the study on all three continents (North America, Europe and Asia).
• Our partners Teva Pharmaceuticals Industries (Israel) and Orient Europharma (Taiwan) enrolled patients in their respective territories.
• We produced multiple lots of Multikine in our manufacturing facility near Baltimore, Maryland, USA and provided drug in sufficient amounts at all clinical sites.
I am constantly being asked how the study is going. As you may know, I am not allowed to discuss the study results at this early stage. However, that being said, our confidence may be best expressed by the decision made to expand the trial into four extra territories at additional expense and effort, with the help of our partner Teva in certain areas. We are doing so because we want to complete the study to prove Multikine’s effectiveness as quickly as possible and hopefully receive marketing approval from the regulators.
If we are able to replicate the promising results seen in our earlier studies and prove that Multikine increases the overall survival of cancer patients by 10% (the study’s primary end point) or more, how much value will this create for our shareholders? No one knows exactly, but it should be significant. By way of example, in 2011 we witnessed the largest acquisition ever of a company with products still in clinical development, not yet on the market. Gilead Sciences bought Pharmasset (Hepatitis C) for about $11 billion in cash. The take home message from this acquisition is clear. Established pharmaceutical companies are willing to pay very large amounts of money for products that address both a large market and represent an unmet medical need. They prefer to wait until most of the risk has been taken off the table. Multikine addresses advanced primary (not yet treated) head and neck cancer, about 5-6% of the world’s cancer cases, clearly a large market. Advanced primary head and neck cancer also represents a clear unmet medical need.
The processes of manufacturing of biological substances and running clinical trials in cancer are extremely complex. We are able to do both because we have assembled a team of world experts who share our vision to help cancer patients. We thank you for your continued support and wish you a very happy, healthy and prosperous 2012.
Sincerely,
Geert Kersten
Maximilian de Clara
Chief Executive Officer
President
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
When used in this report, the words "intends," "believes," "anticipated," “plans” and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2011. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
.
.
Contact:.
.
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
MogD
schrieb am 16.05.12 15:41:22
Beitrag Nr.7251
(43.173.340)
Antwort
Zitat
Antwort auf Beitrag Nr.:
43.172.076 von Umckaloabo am 16.05.12
11:47:45Das sehen die Investoren zum Handelsbeginn
ähnlich.
Eigentlich alles wie immer.
Eigentlich alles wie immer.
Umckaloabo
schrieb am 16.05.12 11:47:45
Beitrag Nr.7250
(43.172.076)
Antwort
Zitat
Alles was ich bis jetzt gelesen habe ist wenig überzeugend.
Ich habd das schon geahnt. Nur wage Dinge und immer im Konjunktiv gesprochen. Vorliegende Ergebnisee sehr differenziert. Das wird keine Kursbewegung nach sich ziehen. Wahrscheinlich müssen wir noch ein halbes Jahr warten. Wieder eine Enttäuschung.
Ich habd das schon geahnt. Nur wage Dinge und immer im Konjunktiv gesprochen. Vorliegende Ergebnisee sehr differenziert. Das wird keine Kursbewegung nach sich ziehen. Wahrscheinlich müssen wir noch ein halbes Jahr warten. Wieder eine Enttäuschung.
ALF-FRED
schrieb am 15.05.12 16:19:21
Beitrag Nr.7249
(43.167.967)
Bewertung: 1 x
Antwort
Zitat
CEL-SCI's Chief Scientific Officer Presents at Cancer Symposium
CEL-SCI Corporation (NYSE MKT: CVM) announced that its Chief Scientific Officer, Eyal Talor, Ph.D., is making a presentation at 4:30 p.m. today in New York at the New York Academy of Sciences Symposium. This symposium will highlight current approaches in cancer immunotherapy and immunomodulation, and emerging cancer vaccines. The presentation is titled: "Multikine® Cancer Immunotherapy: Mechanism of Action, Clinical Experience, Phase III Global Study and Possible New Standard of Care".
It is possible to sign up to listen to this presentation at: http://www.nyas.org/Events/Detail.aspx?cid=18f4ea4e-1fd0-438c-9ff1-3bc8ca3ce4af.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval.Multikine has not been licensed or approvedfor sale, barter or exchangeby the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2011. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contacts:
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
© 2012 Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) announced that its Chief Scientific Officer, Eyal Talor, Ph.D., is making a presentation at 4:30 p.m. today in New York at the New York Academy of Sciences Symposium. This symposium will highlight current approaches in cancer immunotherapy and immunomodulation, and emerging cancer vaccines. The presentation is titled: "Multikine® Cancer Immunotherapy: Mechanism of Action, Clinical Experience, Phase III Global Study and Possible New Standard of Care".
It is possible to sign up to listen to this presentation at: http://www.nyas.org/Events/Detail.aspx?cid=18f4ea4e-1fd0-438c-9ff1-3bc8ca3ce4af.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval.Multikine has not been licensed or approvedfor sale, barter or exchangeby the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2011. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contacts:
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
© 2012 Business Wire
Plaste
schrieb am 15.05.12 08:27:42
Beitrag Nr.7248
(43.165.175)
Bewertung: 1 x
Antwort
Zitat
schlumpftrader
schrieb am 14.05.12 14:03:21
Beitrag Nr.7247
(43.161.893)
Antwort
Zitat
hallo,
guckt euch mal bei www.nasdaq.com die pre-market quote von CEL-SCI an.
was für eine augenweide!
auch wenn am ende des heutigen tages nicht viel davon übrig bleiben sollte, so ist das zumindest jetzt einfach nur schöööön.
bye
schlumpftrader
guckt euch mal bei www.nasdaq.com die pre-market quote von CEL-SCI an.
was für eine augenweide!
auch wenn am ende des heutigen tages nicht viel davon übrig bleiben sollte, so ist das zumindest jetzt einfach nur schöööön.
bye
schlumpftrader
ALF-FRED
schrieb am 14.05.12 06:15:26
Beitrag Nr.7246
(43.159.901)
Antwort
Zitat
binda
schrieb am 11.05.12 14:38:21
Beitrag Nr.7245
(43.153.008)
Bewertung: 1 x
Antwort
Zitat
MarketWire · Mehr Nachrichten von MarketWire
Small Biotech Companies Look to Benefit From Improvement of U.S. Patent System / Five Star Equities Provides Stock Research on Cardium Therapeutics and CEL-SCI
NEW YORK, NY -- (Marketwire) -- 05/11/12 -- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of quality companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Cardium Therapeutics Inc. (NYSE Amex: CXM) and CEL-SCI Corporation (NYSE: CVM).
Access to the full company reports can be found at:
www.FiveStarEquities.com/CXM
www.FiveStarEquities.com/CVM
The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a "first to invent" to a "first to file" system. The majority of countries around the world have already adopted the "first to file" system. The AIA will help benefit biotech companies "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system." BIO President and CEO Jim Greenwood stated in a press release: "Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood.
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs. For the fourth quarter ended December 31, 2011, the Company presented a loss from operations of $1.9 million, compared to a $1.5 million loss from operations for the fourth quarter in 2010.
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine, currently being studied in a pivotal global Phase III clinical trial. The company reported that net loss available to shareholders for the quarter ended December 31, 2011 was $4,156,833 versus $6,250,952 during the same quarter a year prior.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Five Star Equities
Email Contact
Small Biotech Companies Look to Benefit From Improvement of U.S. Patent System / Five Star Equities Provides Stock Research on Cardium Therapeutics and CEL-SCI
NEW YORK, NY -- (Marketwire) -- 05/11/12 -- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of quality companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Cardium Therapeutics Inc. (NYSE Amex: CXM) and CEL-SCI Corporation (NYSE: CVM).
Access to the full company reports can be found at:
www.FiveStarEquities.com/CXM
www.FiveStarEquities.com/CVM
The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a "first to invent" to a "first to file" system. The majority of countries around the world have already adopted the "first to file" system. The AIA will help benefit biotech companies "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system." BIO President and CEO Jim Greenwood stated in a press release: "Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood.
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs. For the fourth quarter ended December 31, 2011, the Company presented a loss from operations of $1.9 million, compared to a $1.5 million loss from operations for the fourth quarter in 2010.
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine, currently being studied in a pivotal global Phase III clinical trial. The company reported that net loss available to shareholders for the quarter ended December 31, 2011 was $4,156,833 versus $6,250,952 during the same quarter a year prior.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Five Star Equities
Email Contact
ALF-FRED
schrieb am 10.05.12 14:35:40
Beitrag Nr.7244
(43.147.273)
Bewertung: 2 x
Antwort
Zitat
ALF-FRED
schrieb am 07.05.12 00:26:45
Beitrag Nr.7243
(43.128.059)
Antwort
Zitat
http://www.nyas.org/Events/Detail.aspx?cid=18f4ea4e-1fd0-438…
unter sponsors :
Academy Friends
Bristol-Myers Squibb
CEL-SCI Corporation
unter sponsors :
Academy Friends
Bristol-Myers Squibb
CEL-SCI Corporation
Plaste
schrieb am 03.05.12 08:31:14
Beitrag Nr.7242
(43.113.738)
Bewertung: 2 x
Antwort
Zitat
http://www.oep.com.tw/eng/business/MA-RA-Licensing.aspx
Cancer Vaccines and Cancer Immunotherapy & Immunomodulation
Tuesday, May 15, 2012 | 12:00 PM - 5:00 PM
The New York Academy of Sciences
http://www.nyas.org/Events/Detail.aspx?cid=18f4ea4e-1fd0-438…
unter Speakers oder Abstracts lesen
Bin ja mal gespannt ob es am 15 Mai interessante News gibt. Ich denke das viele drauf spekulieren werden.
Aus Erfahrung wissen wir ja, das dem nicht so sein sollte.
mfg Plaste
ALF-FRED
schrieb am 01.05.12 12:34:58
Beitrag Nr.7241
(43.107.142)
Antwort
Zitat
wenn es heute rappelt liegen alle besoffen unter dem
Maibaum 
http://seekingalpha.com/article/545051-cel-sci-corp-synergy-…
ALF-FRED
schrieb am 01.05.12 02:57:36
Beitrag Nr.7240
(43.106.485)
Antwort
Zitat
MogD
schrieb am 30.04.12 19:07:13
Beitrag Nr.7239
(43.105.460)
Antwort
Zitat
Antwort auf Beitrag Nr.:
43.105.393 von ALF-FRED am 30.04.12
18:50:40Es geht auf Mitte Mai zu - die ersten Ergebnisse
der Phase III werden erwartet und da wollen wohl einige dabei
sein.
Was denn nun wirklich kommt wird sich dann zeigen - alles neu macht der Mai, hieße für Cel mal Gewinne statt der üblichen Abwärtsbewegungen
Was denn nun wirklich kommt wird sich dann zeigen - alles neu macht der Mai, hieße für Cel mal Gewinne statt der üblichen Abwärtsbewegungen
Pays82
schrieb am 30.04.12 19:02:35
Beitrag Nr.7238
(43.105.439)
Antwort
Zitat
Antwort auf Beitrag Nr.:
43.105.393 von ALF-FRED am 30.04.12
18:50:40Ja, langsam aber stetig hoch.
Schon seit Tagen sieht die Kursentwicklung meines erachtens sehr gut
aus!
Grüsse Pays82
Schon seit Tagen sieht die Kursentwicklung meines erachtens sehr gut
aus!
Grüsse Pays82
ALF-FRED
schrieb am 30.04.12 18:50:40
Beitrag Nr.7237
(43.105.393)
Antwort
Zitat
Na, was kommt denn da bei unserem Schätzchen ???
reblis
schrieb am 21.04.12 07:06:29
Beitrag Nr.7236
(43.069.001)
Antwort
Zitat
http://www.smallcapnetwork.com/Take-the-Hint-Being-Dropped-By-CEL-SCI-Corporation-AMEX-CVM/s/via/1789/article/view/p/mid/3/id/127/
Plaste
schrieb am 19.04.12 22:10:55
Beitrag Nr.7235
(43.063.294)
Bewertung: 2 x
Antwort
Zitat
ALF-FRED
schrieb am 13.04.12 21:29:04
Beitrag Nr.7234
(43.037.906)
Bewertung: 1 x
Antwort
Zitat
[ Seite: 1, 2, 3 … 725, 726, 727, neuster Beitrag ]
Geben Sie Ihre Bewertung zu dieser Seite: sehr gut
1
2
3
4
5
6 schlecht
Problem melden?
Impressum | Werben | Jobs | Allgemeine Nutzungsbestimmungen | Disclaimer | Archiv | Sitemap | Hilfe | Kontakt | RSS |
wallstreet:online AG | Börsen- & Finanzwidgets für Ihre Homepage |
Kurse:
Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min.
Alle Angaben ohne Gewähr. Copyright © 1998-2012 wallstreet:online AG - Alle Rechte vorbehalten.